629 related articles for article (PubMed ID: 29774034)
1. Targeting VEGF/VEGFR to Modulate Antitumor Immunity.
Yang J; Yan J; Liu B
Front Immunol; 2018; 9():978. PubMed ID: 29774034
[TBL] [Abstract][Full Text] [Related]
2. Modulation of immunity by antiangiogenic molecules in cancer.
Terme M; Colussi O; Marcheteau E; Tanchot C; Tartour E; Taieb J
Clin Dev Immunol; 2012; 2012():492920. PubMed ID: 23320019
[TBL] [Abstract][Full Text] [Related]
3. Direct and indirect regulation of the tumor immune microenvironment by VEGF.
Zhang Y; Brekken RA
J Leukoc Biol; 2022 Jun; 111(6):1269-1286. PubMed ID: 35466428
[TBL] [Abstract][Full Text] [Related]
4. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.
Tamura R; Tanaka T; Akasaki Y; Murayama Y; Yoshida K; Sasaki H
Med Oncol; 2019 Nov; 37(1):2. PubMed ID: 31713115
[TBL] [Abstract][Full Text] [Related]
5. Synergy between tumor immunotherapy and antiangiogenic therapy.
Nair S; Boczkowski D; Moeller B; Dewhirst M; Vieweg J; Gilboa E
Blood; 2003 Aug; 102(3):964-71. PubMed ID: 12689940
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
Schenone S; Bondavalli F; Botta M
Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
[TBL] [Abstract][Full Text] [Related]
8. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment.
Bourhis M; Palle J; Galy-Fauroux I; Terme M
Front Immunol; 2021; 12():616837. PubMed ID: 33854498
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.
de Aguiar RB; de Moraes JZ
Front Immunol; 2019; 10():1023. PubMed ID: 31156623
[TBL] [Abstract][Full Text] [Related]
10. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
13. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
14. TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors.
Ibberson M; Bron S; Guex N; Faes-van't Hull E; Ifticene-Treboux A; Henry L; Lehr HA; Delaloye JF; Coukos G; Xenarios I; Doucey MA
Clin Cancer Res; 2013 Jul; 19(13):3439-49. PubMed ID: 23649001
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.
Fricke I; Mirza N; Dupont J; Lockhart C; Jackson A; Lee JH; Sosman JA; Gabrilovich DI
Clin Cancer Res; 2007 Aug; 13(16):4840-8. PubMed ID: 17699863
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
17. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
18. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.
Baka S; Clamp AR; Jayson GC
Expert Opin Ther Targets; 2006 Dec; 10(6):867-76. PubMed ID: 17105373
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
20. VEGF as a mediator of tumor-associated immunodeficiency.
Ohm JE; Carbone DP
Immunol Res; 2001; 23(2-3):263-72. PubMed ID: 11444391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
